Inner Banner
Kimotar (Erlotinib)

Kimotar (Erlotinib)

Send to friends
×
Your Email :*
Friend Email :*
Your Name :
Your Massage :
Security Code:*
captcha
Rate it : 

Kimotar® inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. Kimotar® expressed on the cell surface of healthy cells and cancer cells, and prevents autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signaling.
It is used for themanagement of locally advanced or metastatic non-small cell lung cancer either in disease that is unresponsive to other therapy, or as maintenance monotherapy in those with stable disease after platinum-based first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.




DOSAGE AND ADMINISTRATION
    Treatment of locally advanced or metastatic non-small cell lung cancer
    150 mg daily. Dosage reduction may be required for patients with hepatic impairment.
    Pancreatic Cancer, treatment of locally advanced, unresectable or metastatic pancreatic Cancer in Combination with gemcitabine: 100 mg Daily, in combination with gemcitabine
INDICATIONS
    For the first-line treatment of metastatic non-small cell lung cancer in which tumors have epidermal growth factor receptor (EGFR).
    Treatment of locally advanced, unresectable or metastatic pancreatic Cancer in Combination with gemcitabine:
WARNINGS AND PRECAUTIONS

 • Interstitial Lung Disease (ILD)-like events, including fatalities have been infrequently reported. Interrupt Erlotinib if acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever occur. Discontinue Erlotinib if ILD is diagnosed.

• Cases of acute renal failure (including fatalities), and renal insufficiency have been reported. Interrupt Erlotinib in the event of dehydration. Monitor renal function and electrolytes in patients at risk of dehydration.

• Cases of hepatic failure and hepatorenal syndrome (including fatalities) have been reported. Monitor periodic liver function testing. Interrupt or discontinue Erlotinib if liver function changes are severe.

• Monitor patients with hepatic impairment closely. Interrupt or discontinue Erlotinib if changes in liver function are severe

• Gastrointestinal perforations, including fatalities, have been reported. Discontinue Erlotinib.

• Bullous and exfoliative skin disorders, including fatalities, have been reported. Interrupt or discontinue Erlotinib

• Myocardial infarction/ischemia has been reported, including fatalities, in patients with pancreatic cancer.

• Cerebrovascular accidents, including a fatality, have been reported in patients with pancreatic cancer.

• Microangiopathic Hemolytic Anemia with thrombocytopenia has been reported in patients with pancreatic cancer.

• Corneal perforation and ulceration have been reported. Interrupt or discontinue Erlotinib

• International Normalized Ratio (INR) elevations and bleeding events, some associated with concomitant warfarin administration have been reported. Monitor patients taking warfarin or other coumarin-derivative anticoagulants.

• Erlotinib can cause fetal harm when administered to a pregnant woman. Women should be advised to avoid pregnancy while on Erlotinib.

DRUG INTERACTIONS
    Interact with Analgesics, Antacids, Antibacterials, Anticoagulants, Antifungals, Antipsychotics, Antivirals, Cytotoxics, Ulcer-healing Drugs.